#United States #AbbVie #North Chicago #IBD #Risankizumab

AbbVie's Innovative Advances in IBD Treatment Presented at DDW 2026

AbbVie, a prominent leader in the field of gastrointestinal diseases, has recently revealed groundbreaking long-term data aimed at refining the treatment protocols for Inflammatory Bowel Disease (IBD). These findings were shared at the 2026 Digestive Disease Week (DDW) held in Chicago from May 2 to 5. The presentations included a comprehensive collection of 18 abstracts that focus primarily on Crohn's disease and ulcerative colitis, specifically emphasizing the real-world evidence supporting their treatment options—Risankizumab (Skyrizi) and Upadacitinib (Rinvoq).

Dr. Andrew Anisfeld, AbbVie’s Vice President of Global Medical Affairs for Immunology, highlighted the company’s commitment to enhancing IBD treatment through a diverse portfolio comprising both established and investigational therapies. He emphasized how the research showcased at DDW contributes to a deeper understanding of IBD and bolsters clinical and endoscopic effects of Risankizumab and Upadacitinib.

Key Findings from the Presentations

One of the primary studies discussed was the ASPIRE-CD trial outcomes, which analyzed real-world data from patients treated with Risankizumab for moderate to severe active Crohn’s disease. The findings demonstrated significant and sustained improvements in symptoms such as abdominal pain, urgency, and stool consistency after 52 weeks. Notably, a considerable reduction in corticosteroid use from 34% at baseline to 7% at week 52 was observed, alongside a drop in over-the-counter medication usage from 72% to 49%.

Furthermore, an impressive 77% of patients reported enhancements in their quality of life associated with the treatment after one year, indicating substantial improvements in overall well-being, work productivity, and daily activities. The study noted a marked rise in overall satisfaction with Crohn’s treatment, increasing from 50% at baseline to about 87% by week 52, especially for those continuing with Risankizumab, where satisfaction peaked at 92%.

Another compelling aspect of the research was the low switching rate for patients undergoing treatment with Risankizumab, which stood at merely 14%. This contrasts significantly with other biologics such as Ustekinumab (21%), Vedolizumab (30%), Infliximab (33%), and Adalimumab (36%), illustrating the relative stability and effectiveness of Risankizumab in real-world settings.

In conjunction with these findings, AbbVie also presented data related to Upadacitinib, which shed light on the decreased risk of hospitalization and emergency department visits associated with switching patients from other therapies to Upadacitinib.

In a post-hoc analysis concerning patients with perianal fistulizing Crohn's disease, treatment with Upadacitinib over 52 weeks showed notable endoscopic improvements as indicated by reductions in the Simple Endoscopic Score for Crohn’s Disease (SES-CD). This was particularly remarkable for patients previously unresponsive to anti-tumor necrosis factor (TNF) therapies.

Conclusion

The data shared at DDW 2026 represents significant progress in the management of IBD, underlining AbbVie's ongoing commitment to improving the lives of patients with inflammatory bowel diseases. The results from these extensive studies not only solidify the evidence for the effectiveness and safety of Risankizumab and Upadacitinib but also redefine treatment expectations for healthcare providers and patients alike.

For further insights, detailed abstracts from the 2026 DDW presentations can be accessed online. AbbVie's dedication to addressing serious health challenges through innovative therapies continues to pave the way for better patient outcomes in the future.